TRUSELTIQ
These highlights do not include all the information needed to use TRUSELTIQ safely and effectively. See full prescribing information for TRUSELTIQ. TRUSELTIQ (infigratinib) capsules, for oral use Initial U.S. Approval: 2021
af9a96cf-1cd7-8ace-e053-2a95a90a18cc
HUMAN PRESCRIPTION DRUG LABEL
Feb 7, 2022
QED Therapeutics, Inc.
DUNS: 081223065
Products 4
Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.
infigratinib
Product Details
FDA regulatory identification and product classification information
FDA Identifiers
Product Classification
Product Specifications
INGREDIENTS (1)
infigratinib
Product Details
FDA regulatory identification and product classification information
FDA Identifiers
Product Classification
Product Specifications
INGREDIENTS (1)
infigratinib
Product Details
FDA regulatory identification and product classification information
FDA Identifiers
Product Classification
Product Specifications
INGREDIENTS (1)
infigratinib
Product Details
FDA regulatory identification and product classification information